2026 Interim Report
Filed with HKEX · Stock code 7630 · · 61 pages · English
2 Corporate Information 4 Financial Highlights 5 Business Highlights 8 Management Discussion and Analysis 26 Corporate Governance and Other Information 39 Independent Review Report 40 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 41 Interim Condensed Consolidated Statement of Financial Position 43 Interim Condensed Consolidated Statement of Changes in Eq
IMPACT Therapeutics, Inc. on 6ix
Earlier from IMPACT Therapeutics
- IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
- Articles of association
- Next Day Disclosure Return
Later from IMPACT Therapeutics
- Voluntary announcement - positive CHMP opinion for senaparib, as potential first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow IMPACT Therapeutics into a list and get an email when it puts out news.
Follow IMPACT Therapeutics